Nurix Therapeutics
NRIX
101 hedge funds and large institutions have $1.28B invested in Nurix Therapeutics in 2021 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 39 increasing their positions, 10 reducing their positions, and 5 closing their positions.
660% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 5
290% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 10
49% more funds holding
Funds holding: 68 → 101 (+33)
33% more funds holding in top 10
Funds holding in top 10: 6 → 8 (+2)
18% more capital invested
Capital invested by funds: $1.09B → $1.28B (+$196M)
8.01% more ownership
Funds ownership: 85.28% → 93.29% (+8%)
67% less call options, than puts
Call options by funds: $6K | Put options by funds: $18K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$94.7M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$39.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$35.1M |
| 4 |
Jennison Associates
New York
|
+$27.3M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
+$25.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
-$42M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$41.1M |
| 3 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$34.6M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$7.57M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$5.3M |
NRIX Hedge Fund Activity: Q1 2021 in Review
101 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q1 2021, worth a combined $1.28B — up 18% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new NRIX positions and 5 closed out — a net gain of 33 holders — while 39 added to existing stakes and 10 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $94.7M. The largest seller was Foresite Capital Management IV, cutting an estimated $42M.
- 101 institutional investors held Nurix Therapeutics (NRIX) as of Q1 2021, up from 68 in Q4 2020.
- Funds reported $1.28B of Nurix Therapeutics stock for Q1 2021, up 18% quarter-over-quarter.
- 38 funds opened new Nurix Therapeutics positions in Q1 2021 and 5 closed out, a net change of +33 holders.
- The largest Nurix Therapeutics buyer in Q1 2021 was T. Rowe Price Associates, an estimated $94.7M added.
- The largest Nurix Therapeutics seller in Q1 2021 was Foresite Capital Management IV, an estimated $42M sold.
Based on aggregated 13F filings for Q1 2021.